No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
GNI Group Ltd. is a global biopharmaceutical enterprise dedicated to the research, development, manufacturing, and commercialization of both modern pharmaceuticals and traditional Chinese medicines. The company's lead product, Etuary, is currently available for the treatment of idiopathic pulmonary fibrosis. Beyond this, Etuary is undergoing further clinical evaluation: it is in Phase III trials for connective tissue disease-associated interstitial lung disease, and in Phase II along with a pre-Phase III pilot study for radiation pneumonitis. Investigations are also underway for its application in diabetic nephropathy. GNI Group Ltd.'s pipeline additionally features F351, which is in Phase II development for liver fibrosis; F573, an early-stage compound in pre-clinical testing for acute-on-chronic liver failure; and Tamibarotene, intended for the treatment of acute promyelocytic leukemia. Established in 2001, the company's headquarters are located in Tokyo, Japan.
www.gnipharma.comNo one on the platform currently holds 2160.T.
No tracked institution reports a position in 2160.T as of their last filing.
No one on the platform has traded 2160.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 13.7% | 22.4% | ||||
| Profit Margin % | -16.4% | 6.0% | -0.5% | |||
| Free Cash Flow Margin % | -10.2% | -1.5% | -6.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $40.2B | +43.8% | $15.29 | $13.91–$16.66 | — | 1 |
| 2027 | $62.1B | +54.5% | $86.08 | $67.60–$104.56 | — | 2 |
| 2028 | $100.8B | +62.3% | $129.55 | $104.02–$155.07 | — | 2 |
| 2029 | $109.6B | +8.8% | $148.56 | $135.18–$161.93 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-14 | $-61.64 | $2.49 | +104.0% |
| 2026-05-15 | $-2.74 | $-38.20 | -1294.2% |
| 2026-02-13 | $224.64 | $-74.44 | -133.1% |
| 2025-11-14 | $10.82 | $8.54 | -21.1% |
| 2025-08-14 | $-109.70 | $-7.62 | +93.1% |
| 2025-05-15 | $27.86 | $-10.57 | -137.9% |
| 2025-02-14 | $113.19 | $-6.53 | -105.8% |
| 2024-11-14 | $13.04 |
| $19.48 |
| +49.4% |
| -0.12% |
| $166.4B |
| — |
| 4553.TTowa Pharmaceutical Co., Ltd. | $3625.00 | +2.11% | $178.5B | — |
| 4565.TNxera Pharma Co., Ltd. | $1233.00 | +0.90% | $113.1B | — |
Source: Financial Modeling Prep · peers by sector/industry